/

Società

Cu

Non verificato

Curi Bio

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaSaluteScienza

11 comunicati stampa

Guarda tutti i comunicati

14/10/2026

Curi Bio Expands the Curiverse™ with New Disease Models, Casting Kits, and Application-Ready Solutions

Fonte

Emittente

1.00

0

15/09/2026

FDA Accepts Curi Bio’s Letter of Intent into ISTAND Program to Qualify 3D Neuromuscular Junction Assay as a Non-Animal Replacement for Botulinum Toxin Potency Testing

Fonte

Emittente

1.00

0

26/05/2026

Scienza

Cardiologia

Biologia

Biotecnologia

Farmaceutica

Salute

Eventi

Fiere

Industria

Curi Bio Launches the Curiverse™ at MPS 2026: The Industry’s First Closed-Loop Ecosystem for Industrial-Scale, Human-Relevant Drug Discovery

Fonte

Emittente

1.00

0

20/03/2026

Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology

Fonte

Emittente

1.00

0

12/01/2026

Curi Bio Launches Asia-Pacific Hub, Delivering Greater Support to its Growing APAC Business

Fonte

Emittente

1.00

0

02/12/2025

Curi Bio Secures $10M Series B to Scale Human-Relevant Preclinical Platforms and Advanced Data Analysis for Drug Discovery

Fonte

Emittente

1.00

0

30/04/2025

Curi Bio and Cook MyoSite Announce Strategic Partnership

Fonte

Emittente

1.00

0

08/04/2025

Biotecnologia

Salute

Scienza

Farmaceutica

Curi Bio Celebrates Grand Opening of New Global Headquarters in Seattle

Fonte

Emittente

1.00

0

19/12/2024

Curi Bio Unlocks Advanced Cardiac Insights with Novoheart Integration

Fonte

Emittente

1.00

0

22/11/2024

Multimedialità

Biotecnologia

Tecnica

Associazioni/Professionisti

Salute

Farmaceutica

Scienza

Medicina - Varie

Eventi

Curi Bio Recognized as a 2024 Deloitte Technology Fast 500 Winner

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0